Wang Wei, Li Guang-Yao, Zhu Jian-Yu, Huang Da-Bing, Zhou Hang-Cheng, Zhong Wen, Ji Chu-Shu
Department of Medical Oncology, Anhui Provincial Hospital, Anhui Medical University, 17# Lujiang Road, Hefei, 230001, People's Republic of China.
Med Oncol. 2015 Apr;32(4):131. doi: 10.1007/s12032-015-0574-2. Epub 2015 Mar 22.
Angiogenic factor with G-patch and FHA domains 1 (AGGF1) is a factor implicating in vascular differentiation and angiogenesis. Several lines of evidence indicate that aberrant expression of AGGF1 is associated with tumor initiation and progression. The aim of this study was to investigate the expression and prognostic value of AGGF1 in hepatocellular carcinoma (HCC), as well as its relationship with clinicopathological factors and tumor angiogenesis. Immunohistochemistry was performed to evaluate the expression of AGGF1 in HCC and paracarcinomatous tissues collected from 70 patients. Vascular endothelial growth factor (VEGF) and CD34 expression levels were examined in the 70 HCC tissues. Prognostic significance of tumoral AGGF1 expression was determined. Notably, AGGF1 expression was significantly higher in HCC than in surrounding non-tumor tissues (65.7 vs. 25.7 %; P < 0.001). AGGF1 expression was significantly correlated with tumoral VEGF expression and CD34-positive microvessel density. Moreover, AGGF1 expression was significantly associated with tumor size, tumor capsule, vascular invasion, Edmondson grade, alpha-fetoprotein level, and TNM stage. Kaplan-Meier survival analysis showed that high AGGF1 was correlated with reduced overall survival (OS) rate (P = 0.001) and disease-free survival (DFS) rate (P < 0.001). Multivariate analysis identified AGGF1 as an independent poor prognostic factor of OS and DFS in HCC patients (P = 0.043 and P = 0.010, respectively). Taken together, increased AGGF1 expression is associated with tumor angiogenesis and serves as an independent unfavorable prognostic factor for OS and DFS in HCC. AGGF1 may represent a potential therapeutic target for HCC.
含G-结构域和FHA结构域的血管生成因子1（AGGF1）是一种与血管分化和血管生成相关的因子。多项证据表明，AGGF1的异常表达与肿瘤的发生和进展有关。本研究旨在探讨AGGF1在肝细胞癌（HCC）中的表达及预后价值，及其与临床病理因素和肿瘤血管生成的关系。采用免疫组织化学法评估70例患者的HCC组织和癌旁组织中AGGF1的表达。检测70例HCC组织中血管内皮生长因子（VEGF）和CD34的表达水平。确定肿瘤AGGF1表达的预后意义。值得注意的是，HCC中AGGF1的表达明显高于周围非肿瘤组织（65.7%对25.7%；P<0.001）。AGGF1表达与肿瘤VEGF表达及CD34阳性微血管密度显著相关。此外，AGGF1表达与肿瘤大小、肿瘤包膜、血管侵犯、Edmondson分级、甲胎蛋白水平和TNM分期显著相关。Kaplan-Meier生存分析显示，高AGGF1表达与总生存率（OS）降低（P=0.001）和无病生存率（DFS）降低（P<0.001）相关。多因素分析确定AGGF1是HCC患者OS和DFS的独立不良预后因素（分别为P=0.043和P=0.010）。综上所述，AGGF1表达增加与肿瘤血管生成相关，是HCC患者OS和DFS的独立不良预后因素。AGGF1可能是HCC的一个潜在治疗靶点。
